A first‐in‐class, first‐in‐human, phase I trial of CIGB‐552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF‐κB in patients with advanced solid tumors
Vallespi, Maribel G., Mestre, Braulio, Marrero, Maria A., Uranga, Rolando, Rey, Diana, Lugiollo, Martha, Betancourt, Mircea, Silva, Kirenia, Corrales, Danay, Lamadrid, Yanet, Rodriguez, Yamilka, Maceo, Anaelys, Chaviano, Pedro P., Lemos, Gilda, Cabrales, Ania, Freyre, Freya M., Santana, Hector, Garay, Hilda E., Oliva, Brizaida, Fernandez, Julio R.
Published in International journal of cancer (15.09.2021)
Published in International journal of cancer (15.09.2021)
Get full text
Journal Article
Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease
Castro-Suárez, Niurys de, Trame, Mirjam N, Ramos-Suzarte, Mayra, Dávalos, José M, Bacallao-Mendez, Raymed A, Maceo-Sinabele, Anaelys R, Mangas-Sanjuán, Víctor, Reynaldo-Fernández, Gledys, Rodríguez-Vera, Leyanis
Published in Pharmaceutics (26.11.2020)
Published in Pharmaceutics (26.11.2020)
Get full text
Journal Article